LivaNova Therapy for Drug-Resistant Epilepsy Procedures Gets Increased Provider Reimbursement

 – New patient implants assigned to New Technology Ambulatory Payment Classification 1580

– End-of-service procedures elevated to Level 5 APC
– Effective Jan. 1, 2026, will improve economics for hospitals performing Medicare procedures and significantly reduces a known barrier to procedure penetration

https://finance.yahoo.com/news/livanova-vns-therapy-drug-resistant-140000280.html